Abstract
Angiogenesis plays a critical role in human growth and development, as well as tissue repair and maintenance. Though angiogenesis can be stimulated by several metabolites and growth factors, vascular endothelial growth factor (VEGF) appears to be critical for all new vessel growth. VEGF includes several molecules that are classified according to structure and binding characteristics into the following groupings: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor. VEGF binds with 3 trans-membrane receptors (VEGFR1, VEGFR2, and VEGFR3) each of which initiates downstream signaling through intracellular tyrosine kinase activity. Binding to receptors is amplified by neuropilins, which interact with the heparin binding domain of VEGF and favorably present the receptor binding site to the receptor binding domain. Though VEGF may be synthesized by several cell types, the molecule’s primary target is vascular endothelial cells. VEGF exerts several effects on its target tissues: mitogenicity, vascular hyperpermeability, migration, survival factor, vasodilator, and chemoattraction. Two VEGF binding drugs (pegaptanib and ranibizumab) have been developed specifically for intraocular use. Aflibercept is being developed for both ophthalmologic and oncologic use, and bevacizumab has been used off-label to treat ocular diseases. Each of these drugs binds diffusible VEGF, thereby preventing its binding to the trans-membrane receptors. The drugs have undergone extensive pre-clinical trials in animal models.
Keywords: Aflibercept, angiogenesis, bevacizumab, neovascularization, pegaptanib, ranibizumab, vascular endothelial growth factor, VEGF, ophthalmologic, interleukin
Current Drug Therapy
Title:Vascular Endothelial Growth Factor (VEGF) Biochemistry and Development of Inhibitory Drugs
Volume: 7 Issue: 2
Author(s): Michael W. Stewart
Affiliation:
Keywords: Aflibercept, angiogenesis, bevacizumab, neovascularization, pegaptanib, ranibizumab, vascular endothelial growth factor, VEGF, ophthalmologic, interleukin
Abstract: Angiogenesis plays a critical role in human growth and development, as well as tissue repair and maintenance. Though angiogenesis can be stimulated by several metabolites and growth factors, vascular endothelial growth factor (VEGF) appears to be critical for all new vessel growth. VEGF includes several molecules that are classified according to structure and binding characteristics into the following groupings: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor. VEGF binds with 3 trans-membrane receptors (VEGFR1, VEGFR2, and VEGFR3) each of which initiates downstream signaling through intracellular tyrosine kinase activity. Binding to receptors is amplified by neuropilins, which interact with the heparin binding domain of VEGF and favorably present the receptor binding site to the receptor binding domain. Though VEGF may be synthesized by several cell types, the molecule’s primary target is vascular endothelial cells. VEGF exerts several effects on its target tissues: mitogenicity, vascular hyperpermeability, migration, survival factor, vasodilator, and chemoattraction. Two VEGF binding drugs (pegaptanib and ranibizumab) have been developed specifically for intraocular use. Aflibercept is being developed for both ophthalmologic and oncologic use, and bevacizumab has been used off-label to treat ocular diseases. Each of these drugs binds diffusible VEGF, thereby preventing its binding to the trans-membrane receptors. The drugs have undergone extensive pre-clinical trials in animal models.
Export Options
About this article
Cite this article as:
W. Stewart Michael, Vascular Endothelial Growth Factor (VEGF) Biochemistry and Development of Inhibitory Drugs, Current Drug Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157488512800676002
DOI https://dx.doi.org/10.2174/157488512800676002 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Detection and Treatment of Alcohol-Induced Hypertension
Current Hypertension Reviews Toxicological Effects of Dietary Biogenic Amines
Current Nutrition & Food Science Vitamin D Measurement in the Intensive Care Unit: Methodology, Clinical Relevance and Interpretation of a Random Value
Inflammation & Allergy - Drug Targets (Discontinued) Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics A New Direction in Ophthalmic Development: Nanoparticle Drug Delivery Systems
Current Pharmaceutical Design Vasopressin and Terlipressin in Neonates and Children with Refractory Septic Shock
Current Drug Metabolism Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design PREFACE: “The Lower the Better” Association between White-coat Effect-excluded Blood Pressure and Cardiovascular Events in High-risk Hypertension: Insights from SPRINT
Current Hypertension Reviews Immunological Impact of Whey Protein on Peripheral Blood Mononuclear Cells of Patients with Chronic Liver Disease
Current Nutrition & Food Science Opioid-induced Cardioprotection
Current Pharmaceutical Design Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology Chemical and Physical Aspects of the Edible Fractions and Seeds of Jamelao (Syzygium cumini, L. Skeels)
The Natural Products Journal Contractile Mechanisms in Diabetes-Related Erectile Dysfunction
Current Pharmaceutical Design Familial Hypercholesterolemia: Etiology, Diagnosis and New Treatment Options
Current Pharmaceutical Design Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Reliability of Blood Pressure Patterns Defined by a Single 24-Hour Ambulatory Blood Pressure Monitoring: The Case of the Dipping/Non Dipping and Isolated Clinic Hypertension
Current Hypertension Reviews The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art
Current Radiopharmaceuticals